Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim; Sin Gon Kim; Doo Man Kim; Jeong Taek Woo; Hak Chul Jang; Choon Hee Chung; Kyung Soo Ko; Jeong Hyun Park; Yong Soo Park; Sang Jin Kim; Dong Seop Choi

doi:10.1016/j.diabres.2015.09.009

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim, Sin Gon Kim, Doo Man Kim, Jeong Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi

Internal Medicine

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

Original language	English
Pages (from-to)	e27-e30
Journal	Diabetes Research and Clinical Practice
Volume	110
Issue number	3
DOIs	https://doi.org/10.1016/j.diabres.2015.09.009
Publication status	Published - 2015 Dec 1

Bibliographical note

Funding Information:
This study was supported by the Medicine and Bio Project for ‘Development of New Medicine and Medical Material’ (Project No. 70007613, entitled ‘Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus’) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Publisher Copyright:
© 2015 Elsevier Ireland Ltd.

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1016/j.diabres.2015.09.009

Fingerprint Dive into the research topics of 'Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study'. Together they form a unique fingerprint.

Cite this

Kim, S. H., Kim, S. G., Kim, D. M., Woo, J. T., Jang, H. C., Chung, C. H., Ko, K. S., Park, J. H., Park, Y. S., Kim, S. J., & Choi, D. S. (2015). Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. Diabetes Research and Clinical Practice, 110(3), e27-e30. https://doi.org/10.1016/j.diabres.2015.09.009

Kim, Sun Hwa ; Kim, Sin Gon ; Kim, Doo Man ; Woo, Jeong Taek ; Jang, Hak Chul ; Chung, Choon Hee ; Ko, Kyung Soo ; Park, Jeong Hyun ; Park, Yong Soo ; Kim, Sang Jin ; Choi, Dong Seop. / Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks : An open-label extension study. In: Diabetes Research and Clinical Practice. 2015 ; Vol. 110, No. 3. pp. e27-e30.

@article{d855dc59e7b34391807a366c00fc714d,

title = "Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study",

abstract = "We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.",

author = "Kim, {Sun Hwa} and Kim, {Sin Gon} and Kim, {Doo Man} and Woo, {Jeong Taek} and Jang, {Hak Chul} and Chung, {Choon Hee} and Ko, {Kyung Soo} and Park, {Jeong Hyun} and Park, {Yong Soo} and Kim, {Sang Jin} and Choi, {Dong Seop}",

note = "Funding Information: This study was supported by the Medicine and Bio Project for {\textquoteleft}Development of New Medicine and Medical Material{\textquoteright} (Project No. 70007613, entitled {\textquoteleft}Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus{\textquoteright}) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.diabres.2015.09.009",

language = "English",

volume = "110",

pages = "e27--e30",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks : An open-label extension study. / Kim, Sun Hwa; Kim, Sin Gon; Kim, Doo Man; Woo, Jeong Taek; Jang, Hak Chul; Chung, Choon Hee; Ko, Kyung Soo; Park, Jeong Hyun; Park, Yong Soo; Kim, Sang Jin; Choi, Dong Seop.

In: Diabetes Research and Clinical Practice, Vol. 110, No. 3, 01.12.2015, p. e27-e30.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks

T2 - An open-label extension study

AU - Kim, Sun Hwa

AU - Kim, Sin Gon

AU - Kim, Doo Man

AU - Woo, Jeong Taek

AU - Jang, Hak Chul

AU - Chung, Choon Hee

AU - Ko, Kyung Soo

AU - Park, Jeong Hyun

AU - Park, Yong Soo

AU - Kim, Sang Jin

AU - Choi, Dong Seop

N1 - Funding Information: This study was supported by the Medicine and Bio Project for ‘Development of New Medicine and Medical Material’ (Project No. 70007613, entitled ‘Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus’) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. Publisher Copyright: © 2015 Elsevier Ireland Ltd.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

AB - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

UR - http://www.scopus.com/inward/record.url?scp=84955202578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955202578&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2015.09.009

DO - 10.1016/j.diabres.2015.09.009

M3 - Article

C2 - 26458774

AN - SCOPUS:84955202578

VL - 110

SP - e27-e30

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -

Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this